Collegium Pharmaceutical Inc (COLL) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

Total Assets Chart for Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc (COLL) total assets for FY2025 were USD 1.7B, a -0.4% change from FY2024. Collegium Pharmaceutical Inc's total assets grew from USD 9.0M in 2013 to USD 1.7B in 2025 (18240.0% over 12 years). Total assets compound annual growth rate: 5-year CAGR of 20.8%, 10-year CAGR of 32.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$747.48M
Implied Share Price
$22.96
Enterprise Value
$1.70B
Revenue (TTM)
$808.21M
EBITDA
$405.26M
Profit Margin
5.93%
Trailing P/E
18.08
Forward P/E
4.79
Price/Book (MRQ)
4.65
Price/Sales (TTM)
0.92
EV/EBITDA
4.87
EV/Revenue
2.39
Dividend Yield
—
Book Value
$9.60
Free Cash Flow (FY2025)
$327.58M
Free Cash Flow Yield
43.83%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.